跳至主要内容
临床试验/NCT05683535
NCT05683535已完成不适用

Adverse Events Questionnaire for Low Dose Atropine Eye Drops

Scripps Health1 个研究点 分布在 1 个国家目标入组 148 人开始时间: 2018年6月19日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
148
试验地点
1
主要终点
Summary of adverse events by dose level at the time of the adverse event

研究概览

简要总结

Progressive myopia can lead to severe vision loss and is associated with retinal detachment, glaucoma, and other comorbidities. Several studies have shown that off-label, low-dose atropine eye drops slow the progression of myopia. Many eye care providers are now prescribing off-label atropine eye drops for their myopic patients, with the prescribed concentrations varying amongst providers.

The purpose of this study is to determine if low-dose atropine eyedrops used daily, cause adverse effects to the eyes. Patients currently using 0.01%, 0.03%, or 0.05% atropine eye drops obtained from compounding pharmacies will be assessed for associated adverse effects.

详细描述

Eligibility: Myopic patients currently using 0.01%, 0.03%, or 0.05% atropine eye drops, prescribed by the investigator(s).

Patients that meet the eligibility criteria will be given the parental consent form and child assent form (if applicable) during their regularly scheduled office visit. After consent forms are signed and at each follow-up visit, the investigator or study coordinator will begin by querying for adverse events by asking each patient general, non-directed questions, such as "How have you been feeling since the last visit?" Directed questioning and examination will then be done as appropriate. All reported adverse events will be documented on the appropriate CRF. The patients will then continue with their regular eye exam.

Patients enrolled in the study will be assessed for adverse events at each regularly scheduled office visit for the duration of the study (up to 5 years), unless they choose to withdraw from the study.

The study will assess 148 patients using either 0.01%, 0.03%, or 0.05% atropine eye drops (prescribed by the investigator), over a five-year period.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • patients diagnosed with myopia
  • patients must be currently using 0.01%, 0.03%, or 0.05% atropine eye drops daily
  • low-dose atropine eye drops must be prescribed by the principal investigator and obtained from a compounding pharmacy

排除标准

  • patients without myopia
  • patients with myopia, but not using low-dose atropine eye drops

结局指标

主要结局

Summary of adverse events by dose level at the time of the adverse event

时间窗: up to 5 years

Summary of total adverse events and severity of adverse events, by dose level at time of the adverse event

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验